{ "labelLang" : "hun", "responseDate" : "2024-03-29 05:41", "content" : { "otype" : "JournalArticle", "mtid" : 31409391, "status" : "APPROVED", "published" : true, "comment" : "University of Manitoba, Rady Faculty of Health Sciences, Max Rady College of Medicine, Departments of Internal Medicine, Winnipeg, Canada \n University of Manitoba, Rady Faculty of Health Sciences, Max Rady College of Medicineand Endocrinology, Winnipeg, Canada \n University of Manitoba, Rady Faculty of Health Sciences, Max Rady College of Medicine and Seven Oaks Hospital, Chronic Disease Innovation Centre, Winnipeg, Canada \n Cited By :29 \n Export Date: 4 April 2023 \n CODEN: AJKDD \n Correspondence Address: Rampersad, C.GF324, 820 Sherbrook Street, Canada; email: umrampec@myumanitoba.ca", "unhandledTickets" : 0, "deleted" : false, "lastRefresh" : "2023-04-04T14:09:33.397+0000", "lastModified" : "2022-08-03T10:56:37.531+0000", "created" : "2020-08-24T13:04:21.017+0000", "creator" : { "otype" : "Admin", "mtid" : 10071338, "link" : "/api/admin/10071338", "label" : "Molnár-Taga Márta (SE_AOK_1Bel_Onkol_Admin5_MTM, admin)", "familyName" : "Molnár-Taga", "givenName" : "Márta", "published" : true, "snippet" : true }, "lastDuplumSearch" : "2023-04-04T14:08:20.452+0000", "core" : false, "citation" : true, "publicationPending" : false, "type" : { "otype" : "PublicationType", "mtid" : 24, "link" : "/api/publicationtype/24", "label" : "Folyóiratcikk", "code" : 24, "otypeName" : "JournalArticle", "listPosition" : 1, "published" : true, "oldId" : 24, "snippet" : true }, "subType" : { "otype" : "SubType", "mtid" : 10000059, "link" : "/api/subtype/10000059", "label" : "Szakcikk (Folyóiratcikk)", "name" : "Szakcikk", "nameEng" : "Article", "docType" : { "otype" : "PublicationType", "mtid" : 24, "link" : "/api/publicationtype/24", "label" : "Folyóiratcikk", "code" : 24, "otypeName" : "JournalArticle", "listPosition" : 1, "published" : true, "oldId" : 24, "snippet" : true }, "listPosition" : 101, "published" : true, "oldId" : 10000059, "snippet" : true }, "category" : { "otype" : "Category", "mtid" : 1, "link" : "/api/category/1", "label" : "Tudományos", "published" : true, "oldId" : 1, "snippet" : true }, "languages" : [ { "otype" : "Language", "mtid" : 10002, "link" : "/api/language/10002", "label" : "Angol", "name" : "Angol", "nameEng" : "English", "published" : true, "oldId" : 2, "snippet" : true } ], "firstAuthor" : "Rampersad, C.", "authorships" : [ { "otype" : "PersonAuthorship", "mtid" : 92342083, "link" : "/api/authorship/92342083", "label" : "Rampersad, C. ✉", "listPosition" : 1, "share" : 0.0, "first" : true, "last" : false, "corresponding" : true, "familyName" : "Rampersad", "givenName" : "C.", "authorTyped" : true, "editorTyped" : false, "otherTyped" : false, "type" : { "otype" : "AuthorshipType", "mtid" : 1, "link" : "/api/authorshiptype/1", "label" : "Szerző", "code" : 0, "published" : true, "oldId" : 0, "snippet" : true }, "published" : false, "snippet" : true }, { "otype" : "PersonAuthorship", "mtid" : 92342084, "link" : "/api/authorship/92342084", "label" : "Kraut, E.", "listPosition" : 2, "share" : 0.0, "first" : false, "last" : false, "corresponding" : false, "familyName" : "Kraut", "givenName" : "E.", "authorTyped" : true, "editorTyped" : false, "otherTyped" : false, "type" : { "otype" : "AuthorshipType", "mtid" : 1, "link" : "/api/authorshiptype/1", "label" : "Szerző", "code" : 0, "published" : true, "oldId" : 0, "snippet" : true }, "published" : false, "snippet" : true }, { "otype" : "PersonAuthorship", "mtid" : 92342085, "link" : "/api/authorship/92342085", "label" : "Whitlock, R.H.", "listPosition" : 3, "share" : 0.0, "first" : false, "last" : false, "corresponding" : false, "familyName" : "Whitlock", "givenName" : "R.H.", "authorTyped" : true, "editorTyped" : false, "otherTyped" : false, "type" : { "otype" : "AuthorshipType", "mtid" : 1, "link" : "/api/authorshiptype/1", "label" : "Szerző", "code" : 0, "published" : true, "oldId" : 0, "snippet" : true }, "published" : false, "snippet" : true }, { "otype" : "PersonAuthorship", "mtid" : 92342086, "link" : "/api/authorship/92342086", "label" : "Komenda, P.", "listPosition" : 4, "share" : 0.0, "first" : false, "last" : false, "corresponding" : false, "familyName" : "Komenda", "givenName" : "P.", "authorTyped" : true, "editorTyped" : false, "otherTyped" : false, "type" : { "otype" : "AuthorshipType", "mtid" : 1, "link" : "/api/authorshiptype/1", "label" : "Szerző", "code" : 0, "published" : true, "oldId" : 0, "snippet" : true }, "published" : false, "snippet" : true }, { "otype" : "PersonAuthorship", "mtid" : 92342087, "link" : "/api/authorship/92342087", "label" : "Woo, V.", "listPosition" : 5, "share" : 0.0, "first" : false, "last" : false, "corresponding" : false, "familyName" : "Woo", "givenName" : "V.", "authorTyped" : true, "editorTyped" : false, "otherTyped" : false, "type" : { "otype" : "AuthorshipType", "mtid" : 1, "link" : "/api/authorshiptype/1", "label" : "Szerző", "code" : 0, "published" : true, "oldId" : 0, "snippet" : true }, "published" : false, "snippet" : true }, { "otype" : "PersonAuthorship", "mtid" : 92342088, "link" : "/api/authorship/92342088", "label" : "Rigatto, C.", "listPosition" : 6, "share" : 0.0, "first" : false, "last" : false, "corresponding" : false, "familyName" : "Rigatto", "givenName" : "C.", "authorTyped" : true, "editorTyped" : false, "otherTyped" : false, "type" : { "otype" : "AuthorshipType", "mtid" : 1, "link" : "/api/authorshiptype/1", "label" : "Szerző", "code" : 0, "published" : true, "oldId" : 0, "snippet" : true }, "published" : false, "snippet" : true }, { "otype" : "PersonAuthorship", "mtid" : 92342089, "link" : "/api/authorship/92342089", "label" : "Tangri, N.", "listPosition" : 7, "share" : 0.0, "first" : false, "last" : true, "corresponding" : false, "familyName" : "Tangri", "givenName" : "N.", "authorTyped" : true, "editorTyped" : false, "otherTyped" : false, "type" : { "otype" : "AuthorshipType", "mtid" : 1, "link" : "/api/authorshiptype/1", "label" : "Szerző", "code" : 0, "published" : true, "oldId" : 0, "snippet" : true }, "published" : false, "snippet" : true } ], "title" : "Acute Kidney Injury Events in Patients With Type 2 Diabetes Using SGLT2 Inhibitors Versus Other Glucose-Lowering Drugs: A Retrospective Cohort Study", "identifiers" : [ { "otype" : "PublicationIdentifier", "mtid" : 17131494, "link" : "/api/publicationidentifier/17131494", "label" : "DOI: 10.1053/j.ajkd.2020.03.019", "source" : { "otype" : "PlainSource", "mtid" : 6, "link" : "/api/publicationsource/6", "label" : "DOI", "type" : { "otype" : "PublicationSourceType", "mtid" : 10001, "link" : "/api/publicationsourcetype/10001", "label" : "DOI", "mayHaveOa" : true, "published" : true, "snippet" : true }, "name" : "DOI", "nameEng" : "DOI", "linkPattern" : "https://doi.org/@@@", "publiclyVisible" : true, "published" : true, "oldId" : 6, "snippet" : true }, "validState" : "IDENTICAL", "idValue" : "10.1053/j.ajkd.2020.03.019", "realUrl" : "https://doi.org/10.1053/j.ajkd.2020.03.019", "published" : false, "snippet" : true }, { "otype" : "PublicationIdentifier", "mtid" : 18039550, "link" : "/api/publicationidentifier/18039550", "label" : "WoS: 000573960400023", "source" : { "otype" : "PlainSource", "mtid" : 1, "link" : "/api/publicationsource/1", "label" : "WoS", "type" : { "otype" : "PublicationSourceType", "mtid" : 10003, "link" : "/api/publicationsourcetype/10003", "label" : "Indexelő adatbázis", "mayHaveOa" : false, "published" : true, "snippet" : true }, "name" : "WoS", "nameEng" : "WoS", "linkPattern" : "https://www.webofscience.com/wos/woscc/full-record/@@@", "publiclyVisible" : true, "published" : true, "oldId" : 1, "snippet" : true }, "validState" : "IDENTICAL", "idValue" : "000573960400023", "realUrl" : "https://www.webofscience.com/wos/woscc/full-record/000573960400023", "published" : false, "snippet" : true }, { "otype" : "PublicationIdentifier", "mtid" : 17131493, "link" : "/api/publicationidentifier/17131493", "label" : "Scopus: 85087769651", "source" : { "otype" : "PlainSource", "mtid" : 3, "link" : "/api/publicationsource/3", "label" : "Scopus", "type" : { "otype" : "PublicationSourceType", "mtid" : 10003, "link" : "/api/publicationsourcetype/10003", "label" : "Indexelő adatbázis", "mayHaveOa" : false, "published" : true, "snippet" : true }, "name" : "Scopus", "linkPattern" : "http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-@@@", "publiclyVisible" : true, "published" : true, "oldId" : 3, "snippet" : true }, "validState" : "IDENTICAL", "idValue" : "85087769651", "realUrl" : "http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-85087769651", "published" : false, "snippet" : true } ], "journal" : { "otype" : "Journal", "mtid" : 234, "link" : "/api/journal/234", "label" : "AMERICAN JOURNAL OF KIDNEY DISEASES 0272-6386 1523-6838", "pIssn" : "0272-6386", "eIssn" : "1523-6838", "reviewType" : "REVIEWED", "noIF" : false, "sciIndexed" : true, "scopusIndexed" : true, "lang" : "FOREIGN", "hungarian" : false, "published" : true, "oldId" : 234, "snippet" : true }, "volume" : "76", "issue" : "4", "firstPage" : "471", "lastPage" : "479.e1", "firstPageOrInternalIdForSort" : "471", "publishedYear" : 2020, "abstractText" : "Rationale & Objective: Sodium/glucose cotransporter 2 (SGLT2) inhibitors slow the progression of chronic kidney disease and prevent heart failure events. However, SGLT2 inhibitors may increase the risk for acute kidney injury (AKI). Our objective was to assess whether SGLT2 inhibitor use, compared with all other glucose-lowering drugs (oGLDs), is associated with increased rates of AKI. Study Design: Retrospective cohort study. Setting & Participants: Adults in Manitoba, Canada, with type 2 diabetes mellitus followed up from June 2014 until March 2017. Exposures: Initial SGLT2 inhibitor or oGLD use ascertained through a province-wide outpatient prescription database. Outcome: The primary outcome was incident AKI, identified either by an increase in serum creatinine level and/or hospital discharge codes for AKI while taking glucose-lowering drugs (on-treatment approach). Analytical Approach: A propensity score analysis was used to assemble groups of incident users of SGLT2 inhibitors and a 1:1 matched set of oGLD users. The rate of AKI was compared across matched groups using cause-specific hazards models. Sensitivity analyses considered exposure to be constant throughout follow-up after initiation of the drug treatment (intention-to-treat approach) or incorporated recurrent exposures (new user design). Results: Comparing 4,778 incident users of SGLT2 inhibitors with 4,778 incident users of oGLDs, there were no differences observed in the primary outcome (HR, 0.64; 95% CI, 0.40-1.03; P = 0.06) using an on-treatment approach. In neither set of sensitivity analyses were SGLT2 inhibitors associated with increased risk for AKI. Limitations: Drug choice may have been related to AKI risk, laboratory data were obtained from clinical care, and changes in adverse event reporting may have followed the US Food and Drug Administration warning. There were insufficient data to compare individual SGLT2 inhibitors. Conclusions: Compared with oGLDs, SGLT2 inhibitors were not observed to be associated with increased risk for AKI in a clinical population–based cohort. © 2020", "keywords" : [ { "otype" : "Keyword", "mtid" : 14299, "link" : "/api/keyword/14299", "label" : "drug safety", "published" : true, "oldId" : 14299, "snippet" : true }, { "otype" : "Keyword", "mtid" : 1006305, "link" : "/api/keyword/1006305", "label" : "kidney function", "published" : true, "oldId" : 1006305, "snippet" : true }, { "otype" : "Keyword", "mtid" : 1015240, "link" : "/api/keyword/1015240", "label" : "acute kidney failure", "published" : true, "oldId" : 1015240, "snippet" : true }, { "otype" : "Keyword", "mtid" : 1044596, "link" : "/api/keyword/1044596", "label" : "Type 2 diabetes", "published" : true, "oldId" : 1044596, "snippet" : true }, { "otype" : "Keyword", "mtid" : 1358217, "link" : "/api/keyword/1358217", "label" : "acute renal failure (ARF)", "published" : true, "oldId" : 1358217, "snippet" : true }, { "otype" : "Keyword", "mtid" : 1435772, "link" : "/api/keyword/1435772", "label" : "kidney disease progression", "published" : true, "oldId" : 1435772, "snippet" : true }, { "otype" : "Keyword", "mtid" : 1514480, "link" : "/api/keyword/1514480", "label" : "dapagliflozin", "published" : true, "snippet" : true }, { "otype" : "Keyword", "mtid" : 1527363, "link" : "/api/keyword/1527363", "label" : "Empagliflozin", "published" : true, "snippet" : true }, { "otype" : "Keyword", "mtid" : 1527411, "link" : "/api/keyword/1527411", "label" : "Canagliflozin", "published" : true, "snippet" : true }, { "otype" : "Keyword", "mtid" : 1527426, "link" : "/api/keyword/1527426", "label" : "SGLT2 inhibitor", "published" : true, "snippet" : true }, { "otype" : "Keyword", "mtid" : 1649175, "link" : "/api/keyword/1649175", "label" : "acute kidney injury (AKI)", "published" : true, "snippet" : true }, { "otype" : "Keyword", "mtid" : 1820862, "link" : "/api/keyword/1820862", "label" : "Adverse drug event", "published" : true, "snippet" : true }, { "otype" : "Keyword", "mtid" : 2033042, "link" : "/api/keyword/2033042", "label" : "glucose-lowering drug", "published" : true, "snippet" : true } ], "digital" : true, "printed" : true, "sourceYear" : 2020, "foreignEdition" : true, "foreignLanguage" : true, "fullPublication" : true, "conferencePublication" : false, "nationalOrigin" : false, "missingAuthor" : false, "oaType" : "NONE", "oaCheckDate" : "2023-04-04", "oaFree" : false, "citationCount" : 0, "citationCountUnpublished" : 0, "citationCountWoOther" : 0, "independentCitCountWoOther" : 0, "doiCitationCount" : 0, "wosCitationCount" : 0, "scopusCitationCount" : 0, "independentCitationCount" : 0, "unhandledCitationCount" : 0, "citingPubCount" : 0, "independentCitingPubCount" : 0, "unhandledCitingPubCount" : 0, "citedPubCount" : 7, "citedCount" : 7, "ratings" : [ { "otype" : "SjrRating", "mtid" : 10860643, "link" : "/api/sjrrating/10860643", "label" : "sjr:D1 (2020) Scopus - Nephrology AMERICAN JOURNAL OF KIDNEY DISEASES 0272-6386 1523-6838", "listPos" : 6, "rankValue" : 0.1, "type" : "journal", "ratingType" : { "otype" : "RatingType", "mtid" : 10002, "link" : "/api/ratingtype/10002", "label" : "sjr", "code" : "sjr", "published" : true, "snippet" : true }, "subject" : { "otype" : "ClassificationExternal", "mtid" : 2727, "link" : "/api/classificationexternal/2727", "label" : "Scopus - Nephrology", "published" : true, "oldId" : 2727, "snippet" : true }, "ranking" : "D1", "calculation" : "DIRECT", "published" : true, "snippet" : true } ], "ratingsForSort" : "D1", "referenceList" : "(2019), https://diabetesatlas.org/en/, International Diabetes Federation. IDF Diabetes Atlas 7th edition., 2015, 26 November ;\n Zhou, B., Lu, Y., Hajifathalian, K., Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants (2016) Lancet, 387 (10027), pp. 1513-1530 ;\n Davies, M.J., D'Alessio, D.A., Fradkin, J., Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) (2018) Diabetes Care, 41 (12), pp. 2669-2701 ;\n Booth, G.L., Kapral, M.K., Fung, K., Tu, J.V., Relation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people: a population-based retrospective cohort study (2006) Lancet, 368 (9529), pp. 29-36 ;\n Perkovic, V., de Zeeuw, D., Mahaffey, K.W., Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials (2018) Lancet Diabetes Endocrinol, 6 (9), pp. 691-704 ;\n Perkovic, V., Jardine, M.J., Neal, B., Canagliflozin and renal outcomes in type 2 diabetes and nephropathy (2019) N Engl J Med, 380 (24), pp. 2295-2306 ;\n Wiviott, S.D., Raz, I., Bonaca, M.P., Dapagliflozin and cardiovascular outcomes in type 2 diabetes (2019) N Engl J Med, 380 (4), pp. 347-357 ;\n Zinman, B., Wanner, C., Lachin, J.M., Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes (2015) N Engl J Med, 373 (22), pp. 2117-2128 ;\n Kosiborod, M., Lam, C.S.P., Kohsaka, S., Cardiovascular events associated with SGLT-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL 2 Study (2018) J Am Coll Cardiol, 71 (23), pp. 2628-2639 ;\n Kosiborod, M., Cavender, M.A., Fu, A.Z., Lower risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors) (2017) Circulation, 136 (3), pp. 249-259 ;\n Lipscombe, L., Booth, G., Butalia, S., Pharmacologic glycemic management of type 2 diabetes in adults (2018) Can J Diabetes, 42, pp. S88-S103 ;\n Food, U.S., (2019), https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-strengthens-kidney-warnings-diabetes-medicines-canagliflozin, Drug Association. FDA Drug Safety Communication: FDA strengthens kidney warnings for diabetes medicines canagliflozin (Invokana, Invokamet) and dapagliflozin (Farxiga, Xigduo XR) | FDA. Published 2016, 27 November ;\n Perlman, A., Heyman, S.N., Matok, I., Stokar, J., Muszkat, M., Szalat, A., Acute renal failure with sodium-glucose-cotransporter-2 inhibitors: analysis of the FDA adverse event report system database (2017) Nutr Metab Cardiovasc Dis, 27 (12), pp. 1108-1113 ;\n Neuen, B.L., Ohkuma, T., Neal, B., Cardiovascular and renal outcomes with canagliflozin according to baseline kidney function data from the CANVAS program (2018) Circulation, 138 (15), pp. 1537-1550 ;\n Wanner, C., Inzucchi, S.E., Lachin, J.M., Empagliflozin and progression of kidney disease in type 2 diabetes (2016) N Engl J Med, 375 (4), pp. 323-334 ;\n Wanner, C., Heerspink, H.J.L., Zinman, B., Empagliflozin and kidney function decline in patients with type 2 diabetes: a slope analysis from the EMPA-REG OUTCOME trial (2018) J Am Soc Nephrol, 29 (11), pp. 2755-2769 ;\n Roos, L.L., Brownell, M., Lix, L., Roos, N.P., Walld, R., MacWilliam, L., From health research to social research: privacy, methods, approaches (2008) Soc Sci Med, 66 (1), pp. 117-129 ;\n Roos, L.L., Nicol, P.J., A research registry: uses, development, and accuracy (1999) J Clin Epidemiol, 52 (1), pp. 39-47 ;\n Roos, N.P., Roos, L.L., Brownell, M., Fuller, E.L., Enhancing policymakers’ understanding of disparities: relevant data from an information-rich environment (2010) Milbank Q, 88 (3), pp. 382-403 ;\n Smith, M., Lix, L.M., Azimaee, M., Assessing the quality of administrative data for research: a framework from the Manitoba Centre for Health Policy (2018) J Am Med Inform Assoc, 25 (3), pp. 224-229 ;\n KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD) (2009) Kidney Int Suppl, 113, pp. S1-S130 ;\n Zarbock, A., John, S., Jörres, A., New KDIGO guidelines on acute kidney injury. practical recommendations D (2014) Anaesthesist, 63 (7), pp. 578-588 ;\n Coca-Perraillon, M., (2007) Local and Global Optimal Propensity Score Matching, , Harvard Medical School Boston, MA ;\n Nadkarni, G.N., Ferrandino, R., Chang, A., Acute kidney injury in patients on SGLT2 inhibitors: a propensity-matched analysis (2017) Diabetes Care, 40 (11), pp. 1479-1485 ;\n Cahn, A., Melzer-Cohen, C., Pollack, R., Chodick, G., Shalev, V., Acute renal outcomes with sodium-glucose co-transporter-2 inhibitors: real-world data analysis. Diabetes (2019) Obes Metab, 21 (2), pp. 340-348 ;\n Jardine, M.J., Mahaffey, K.W., Neal, B., The Canagliflozin and Renal Endpoints in Diabetes With Established Nephropathy Clinical Evaluation (CREDENCE) study rationale, design, and baseline characteristics (2018) Am J Nephrol, 46 (6), pp. 462-472 ;\n Anders, H.J., Davis, J.M., Thurau, K., Nephron protection in diabetic kidney disease (2016) N Engl J Med, 375 (21), pp. 2096-2098 ;\n Heerspink, H.J.L., Johnsson, E., Gause-Nilsson, I., Cain, V.A., Sjöström, C.D., Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving renin-angiotensin blockers (2016) Diabetes Obes Metab, 18 (6), pp. 590-597 ;\n Sano, M., Takei, M., Shiraishi, Y., Suzuki, Y., Increased hematocrit during sodium-glucose cotransporter 2 inhibitor therapy indicates recovery of tubulointerstitial function in diabetic kidneys (2016) J Clin Med Res, 8 (12), pp. 844-847 ;\n Mudaliar, S., Alloju, S., Henry, R.R., Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG OUTCOME study? A unifying hypothesis (2016) Diabetes Care, 39, pp. 1115-1122 ;\n Zeni, L., Norden, A.G.W., Cancarini, G., Unwin, R.J., A more tubulocentric view of diabetic kidney disease (2017) J Nephrol, 30 (6), pp. 701-717 ;\n Vallon, V., Thomson, S.C., Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition (2017) Diabetologia, 60 (2), pp. 215-225 ;\n Yao, D., Wang, S., Wang, M., Lu, W., Renoprotection of dapagliflozin in human renal proximal tubular cells via the inhibition of the high mobility group box 1-receptor for advanced glycation end products-nuclear factor-κB signaling pathway (2018) Mol Med Rep, 18 (4), pp. 3625-3630 ;\n Matthews, D.R., Li, Q., Perkovic, V., Effects of canagliflozin on amputation risk in type 2 diabetes: the CANVAS Program (2019) Diabetologia, 62 (6), pp. 926-938", "hasCitationDuplums" : false, "userChangeableUntil" : "2020-11-24T12:49:03.350+0000", "directInstitutesForSort" : "", "ownerAuthorCount" : 13, "ownerInstituteCount" : 54, "directInstituteCount" : 0, "authorCount" : 7, "contributorCount" : 0, "hasQualityFactor" : true, "link" : "/api/publication/31409391", "label" : "Rampersad C. et al. Acute Kidney Injury Events in Patients With Type 2 Diabetes Using SGLT2 Inhibitors Versus Other Glucose-Lowering Drugs: A Retrospective Cohort Study. (2020) AMERICAN JOURNAL OF KIDNEY DISEASES 0272-6386 1523-6838 76 4 471-479.e1", "template" : "